Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Arcturus Therapeutics Holdings Quick Ratio?
Arcturus Therapeutics HoldingsARCT -5.26%48 Quick Ratio is 5.88 as of Jun. 2026, which is 28% above its 10-year median of 4.61. GuruFocus rates ARCT with a GF Score™ of 48/100 and a GF Value™ of $2.19 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,405 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 65.05% on this metric.
Arcturus Therapeutics Holdings (NAS:ARCT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Arcturus Therapeutics Holdings Quick Ratio Related Terms
Arcturus Therapeutics Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Quick Ratio falls into.
Arcturus Therapeutics Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (ARCT) has a Quick Ratio of 5.88 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Arcturus Therapeutics Holdings and its competitors. This is 28% above median its historical median of 4.61. Over the past decade, Arcturus Therapeutics Holdings' Quick Ratio has ranged from 1.41 to 25.42. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #491 out of 1405 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Arcturus Therapeutics Holdings' Quick Ratio too high?
Arcturus Therapeutics Holdings' current Quick Ratio of 5.88 is 28% above median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 25.42. The Biotechnology industry median Quick Ratio is 3.50. Arcturus Therapeutics Holdings' value of 5.88 is 68% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #491 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Quick Ratio compare to EQ and SMNR?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #491 out of 1405 companies for Quick Ratio. This puts Arcturus Therapeutics Holdings in the upper half of its industry. The industry median Quick Ratio is 3.50. Arcturus Therapeutics Holdings' value of 5.88 is 68% above this benchmark. Historically, Arcturus Therapeutics Holdings' own Quick Ratio has ranged from 1.41 to 25.42 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 3.50, Arcturus Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.50, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Quick Ratio of 5.88 is 68% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Quick Ratio is 5.88, which is 28% above median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.19, compared to a current price of $7.02 — trading 220.5% above its estimated fair value. The current Quick Ratio is 5.88, which is 28% above median its 10-year median of 4.61 and 68% above the Biotechnology industry median of 3.50. Arcturus Therapeutics Holdings' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Quick Ratio is 5.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $7.02 is trading 220.5% above its estimated GF Value™ of $2.19.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
Quick Ratio: 5.88 (28% above median its 10-year median of 4.61)
GF Value™: $2.19 vs. price of $7.02 (220.5% above fair value)
Industry Position: 68% above the Biotechnology median (#491 of 1405)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
48GF Score
Get the complete analysis for ARCT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
